Previous 10 | Next 10 |
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing o...
2023-05-18 10:35:25 ET Catalent ( NYSE: CTLT ) is scheduled to announce Q3 earnings results on Friday, May 19th, before market open. The consensus EPS Estimate is $0.32 (-5.9% Y/Y) and the consensus Revenue Estimate is $1.03B (+1.0% Y/Y). Over the last 2 years, CTLT ...
2023-05-18 01:10:00 ET Summary Earnings season has been better than feared, and we highlight two firms offering differing views on the state of the economy. There’s also one falling Pharma company that (once again) delayed its Q3 results. Broadly, our data show solid di...
2023-05-15 07:55:16 ET Following a trading halt on Friday, Sarepta Therapeutics ( NASDAQ: SRPT ) climbed ~29% in the pre-market as Wall Street reacted to a favorable decision by an FDA advisory committee last week over the company’s marketing application for gene therapy ...
2023-05-14 08:43:41 ET Summary Catalent has seen its share price implode over the last year. The company has seen operational weakness, just when it added quite some debt to pursue bolt-on dealmaking. Real operational challenges, amidst a very leveraged balance sheet, create r...
2023-05-13 15:06:21 ET Catalent ( NYSE: CTLT ) postponed its Q3 earnings release and conference call for a third time and is now scheduled to release its results on Friday. The contract research organization delayed the results to Friday May 19 from Monday as the company work's ...
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2...
2023-05-12 18:31:20 ET A panel of advisors to the US FDA has voted that the benefits of Sarepta Therapeutics' ( NASDAQ: SRPT ) gene therapy SRP-9001 for Duchenne muscular dystrophy outweigh the risks. The vote from members of the Cellular, Tissue, and Gene Therapies Advis...
2023-05-12 15:03:55 ET Shares of contract manufacturer Catalent ( NYSE: CTLT ) continued to tumble on Friday to reach a new 52-week low, while Jefferies reaffirmed its Buy rating despite the company’s recent decisions to lower guidance and delay Q3 financials. Catalent ( ...
2023-05-12 14:07:49 ET NYSE: TJX ROST OTCPK:BURBY BJ CPRT KSS Meanwhile, Chinese tech giants Baidu ( BIDU ) and Alibaba ( BABA ) are set to issue closely observed reports that will attract significant attention. For further details see: Earnings W...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...